Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trinity Biotech (TRIBY) -- Ignore unavailable to you. Want to Upgrade?

To: Keiko who wrote (9356)	5/30/1998 8:26:00 PM
From: DELT1970	Read Replies (1) \| Respond to of 14328

Did all those pints trigger an interest in urine and the collaboration initiated January, 1997 among the company and Calypte Biomedical? I note in 1997 10K for CALY the statement: "New research shows that a combination of urine and blood-based tests can detect antibodies to HIV-1 with greater sensitivity than can be achieved by either test alone. Results of clinical trials reported at the Company show that some individuals who test positive for antibodies to HIV-1, may produce such antibodies in one body fluid but not another. Moreover, researchers from the University of Milan found that individuals demonstrating a strong natural immune response to the HIV-1 virus produce antibodies in urine and vaginal samples, but not in blood, thus potentially simplifying the identification of HIV-resistant individuals." I wonder if FDA is struggling with TRIBY's application in part over this issue?